tDRmapper: challenges and solutions to mapping, naming, and quantifying tRNA-derived RNAs from human small RNA-sequencing data by Sara R. Selitsky & Praveen Sethupathy
METHODOLOGY ARTICLE Open Access
tDRmapper: challenges and solutions
to mapping, naming, and quantifying
tRNA-derived RNAs from human small
RNA-sequencing data
Sara R. Selitsky1,2,3* and Praveen Sethupathy1,2,4
Abstract
Background: Small RNA-sequencing has revealed the diversity and high abundance of small RNAs derived from
tRNAs, referred to as tRNA-derived RNAs. However, at present, there is no standardized nomenclature and there are
no methods for accurate annotation and quantification of these small RNAs. tRNA-derived RNAs have unique
features that limit the utility of conventional alignment tools and quantification methods.
Results: We describe here the challenges of mapping, naming, and quantifying tRNA-derived RNAs and present a
novel method that addresses them, called tDRmapper. We then use tDRmapper to perform a comparative analysis
of tRNA-derived RNA profiles across different human cell types and diseases. We found that (1) tRNA-derived RNA
profiles can differ dramatically across different cell types and disease states, (2) that positions and types of chemical
modifications of tRNA-derived RNAs vary by cell type and disease, and (3) that entirely different tRNA-derived RNA
species can be produced from the same parental tRNA depending on the cell type.
Conclusion: tDRmappernot only provides a standardized nomenclature and quantification scheme, but also
includes graphical visualization that facilitates the discovery of novel tRNA and tRNA-derived RNA biology.
Keywords: tRNA, tDR, Sequencing, RNA modifications, Bioinformatics
Background
Transfer RNAs (tRNAs) are non-coding RNAs that
deliver amino acids to ribosomes during translation.
tRNA-derived RNAs (tDRs) are small RNAs that are
enzymatically processed from either nascent pre-tRNA
transcripts or mature tRNAs [1]. Their regulated biogen-
esis and well-defined 5′ and 3′ ends indicate that they
are not products of tRNA degradation [2]. tDRs are gen-
erated in organisms from all domains of life [3]. They
are derived from most tRNA genes and produced in
varying abundance, in a variety of different sizes, and
from different regions of the tRNA. Several functions have
been attributed to tDRs such as post-transcriptional [4, 5]
and translational repression [6], stress granule formation
[7], and protection from apoptosis [8]; however, all of these
have been in the context of cell culture. The role of tDRs
in human health is only now starting to emerge. tDRs may
play a role in neurodegeneration [9], cancer [5, 10], as well
as immune modulation [11], and we previously showed
that tDRs are significantly increased in the liver tissue of
patients with chronic viral hepatitis and decreased in liver
cancer [2].
Despite the potential biomedical significance of tDRs,
the field is lagging behind other small RNA fields in
terms of genomic annotation and strategies for quantifi-
cation from small RNA-sequencing (small RNA-seq)
data. This is due in large part to: (a) the unique compu-
tational challenges of mapping tDRs from small RNA-
seq data and (b) the lack of a standardized nomenclature
for tDRs.* Correspondence: SaraRSelitsky@gmail.com
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a) While small RNA-seq has enabled the discovery of
tDRs, these small RNAs are difficult to map accurately
for at least three reasons:
(1)Exact copies of tRNA genes are present in
numerous locations throughout the human
genome, and annotation of tRNAs in the human
genome is still incomplete. This means that small
RNA-seq reads corresponding to tRNA-derived
RNAs can map with equal fidelity to numerous
locations throughout the genome (multi-mapping),
which leads to ambiguity about the precise origin
of the tRNA-derived RNA.
(2)tDRs are derived from both the nascent
pre-tRNAs and the processed, mature tRNAs.
The maturation process of eukaryotic tRNAs
includes several steps, such as the removal
of 5′ leader sequence and 3′ trailer
sequence, the addition of a non-templated
“CCA” to the 3′ end, and the excision of
introns. These changes during maturation
need to be accounted for when mapping
tRNA-derived RNA reads. For example,
spliced reads (those derived from the sequence
flanking the spliced intron) or reads that
contain a non-templated 3′-end “CCA” will
not map to the genome.
(3)tRNAs are subject to extensive chemical
modifications at specific nucleotide positions
during maturation [12]. As a result, tDRs most
likely harbor these modifications, which can lead
to errors during cDNA synthesis due to reverse
transcriptase pausing and mis-incorporation of
nucleosides [13]. These errors manifest in small
RNA-seq reads as mismatches and deletions
relative to the reference tRNA sequence.
These mismatches/deletions will be referred to
as “error type.”
b) There is no standardized nomenclature for tDRs.
tDRs are produced in a variety of different sizes,
from a variety of different tRNAs, and from a variety
of different locations within the tRNAs, all of which
present challenges for a coherent naming system.
A standard naming scheme is critical to facilitate
future research. For example, it is at present
extremely difficult to use published studies to define
the bio-distribution of specific tDRs (the tissues and
conditions in which specific tDRs are expressed) be-
cause the same or similar tDR is often referred to by
completely different names (and in some cases
a name is not given at all).
In this study we introduce a tool designed to
address the challenges of mapping, naming, and
quantifying tDRs, called tDRmapper. tDRmapper was
designed specifically for human small RNA-seq data
(single-end, 50x) generated on the Illumina sequen-
cing platform using cDNA libraries that were pre-
pared using the Illumina TruSeq protocol. We used
tDRmapper to analyze publically available small RNA-
seq datasets (total n = 45) from four categories of cell
types/tissues. These analyses helped shape the final
version of the tool and also led to the discovery of
new types of tDR species as well as novel insights
about potentially varying patterns of tRNA modifica-
tions in different human tissues and diseases.
Results and discussion
tDRmapper aligns small RNA-seq reads to tRNA
sequences, allowing for and quantifying mismatches and
deletions. tDRmapper was written with its own string
matching alignment scheme and does not use a previ-
ously developed aligner, such as Bowtie 2 [14]. While
Bowtie 2 does allow for mismatches and deletions, it
was not designed with unique features of tRNAs and
pre-tRNAs in mind. tDRmapper is specifically de-
signed for mapping reads to tRNAs, which have sev-
eral unique features that are described below. Also,
while methods for assessing RNA modifications from
small RNA-seq data have been previously developed,
such as HAMR [13], they do not quantify tDR spe-
cies. tDRmapper defines and quantifies specific tDRs
and automatically generates visualization of both pre-
and mature tDR profiles.
Small RNA-seq datasets from four categories of human
cell types/tissues
We analyzed a diverse array of human small RNA-seq
datasets to guide tool development and to ensure that
tDRmapper is not biased to one specific tissue or dis-
ease. We also used some of the results from these ana-
lyses as examples to illustrate the importance of each
step in tDRmapper.
Previously, we reported that tDRs are highly abun-
dant in liver tissue and both the total tDR abundance
and the relative expression of individual tDRs were
associated with chronic hepatitis B, chronic hepatitis
C, and hepatocellular carcinoma [2]. In this study, the
analysis of the different categories of cell types/tissues
revealed that the high abundance of tDRs is not spe-
cific to liver disease, but rather tDRs are present in
high abundance in other human tissues and fluids as
well (Fig. 1). The four categories of cell types/tissues
are described below:
Primary liver tissue – Chronic viral hepatitis and liver
cancer [2]
Hepatitis B and hepatitis C viruses both infect the
liver, leading to chronic liver infection and cancer.
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Both viruses together are responsible for ~80 % of
the world’s liver cancer cases. Liver tissue was col-
lected during surgical resection in Kanazawa, Japan
and small RNA-seq was performed on the RNA
isolated from matched malignant and non-malignant
tissue from patients with advanced chronic hepatitis B
(n = 4) or chronic hepatitis C (n = 4), as well as from
liver tissue from uninfected individuals (n = 4) under-
going liver surgery due to metastatic colon cancer
(GSE57381).
Primary colon tissue – Crohn’s disease [15]
Crohn’s disease is a chronic inflammatory condition
of the gastrointestinal tract. These datasets were gen-
erated from a study that performed small RNA-seq
on primary colon tissue from subjects with Crohn’s
disease, including both the uninflamed (n = 21) and
inflamed (n = 6) components, as well as colon tissue
from individuals without Crohn’s disease (n = 13). The
small RNA-seq was performed in the same sequen-
cing facility as the liver samples described above
(GSE66209).
Seminal fluid – Prostate cancer [16]
The non-sperm fractions of seminal fluid can be used to
screen for biomarkers of prostate cancer. These datasets
were generated from a study that performed small RNA-
seq on a pooled sample of seminal fluid RNA from men
with prostate cancer (n = 6) and a pooled sample of sem-
inal fluid RNA from men without prostate cancer
(n = 6) (GSE56686).
Stem and progenitor cells – Phases of embryonic
development
The University of California at San Diego, through
the NIH Roadmap Epigenomics Project, generated
small RNA-seq data for ten samples (GSE16256): H1
cells (human embryonic stem cells) with no treatment
(n = 2), H1 cells treated with BMP4 for differentiation
to trophoblasts (n = 2) and mesendoderm (n = 2), H1-
derived neuronal progenitor cells (n = 2), and H1-
derived mesenchymal stem cells (n = 2).
Details of tDRmapper
We developed the first publically available tool, called
tDRmapper, for mapping, naming, and quantification of
tDRs (Fig. 2). Each step of tDRmapper is described
below:
Step 1: Sequencing reads are filtered for quality
tDRmapper takes as input adapter-trimmed small RNA
sequencing reads in FASTQ format. The program then
discards the following types of reads:
(1)If the Phred +33 quality score drops below 28 at
any individual position along the length of the read.
This filter is implemented in order to increase the
likelihood that mismatches/deletions in the reads
with respect to the reference sequence are biological
and not due to errors of the sequencing machine.
The score threshold is very conservative, so the
mismatch/deletion (“error type”) calls are high
confidence.
Fig. 1 Relative abundance of all tRNA-derived RNAs across four categories of human cell types/tissues. Proportion of trimmed and filtered reads
that map to tRNAs in primary colon tissue (control n = 13; Crohn’s disease uninflamed tissue, n = 21; Crohn’s disease inflamed tissue, n = 6), primary liver
tissue (control, n = 4; chronic hepatitis B non-cancer tissue, n = 4; chronic hepatitis C non-cancer tissue, n = 4; chronic hepatitis B associated cancer
tissue, n = 4; chronic hepatitis C associated cancer tissue, n = 4), the non-sperm fraction of seminal fluid (n = 2), and NIH roadmap H1 and H1-derived
cells (H1 cells with no treatment, n = 2; H1-derived trophoblasts, n = 2; H1-derived mesendoderm, n = 2; H1-derived neuronal progenitor cells, n = 2;
H1-derived mesenchymal stem cells, n = 2). Black lines show the median and interquartile range
Selitsky and Sethupathy BMC Bioinformatics  (2015) 16:354 Page 3 of 13
(2)If the read is smaller than 14 nucleotides or
larger than 40. tDRmapper was designed for
single-end 50x small RNA-seq data. Based on
our adapter trimming strategy, successfully
trimmed reads are <41 nts. The lower bound
(14 nts) is especially critical for mitigating
mapping ambiguity (the smaller the read the
more locations it can map to just by chance,
especially when allowing for mismatches and
deletions).
(3)If the read does not occur in the FASTQ file at
least 100 times. This threshold was set based on
Fig. 2 Schematic of tDRmapper. The input into tDRmapper is trimmed small RNA-seq reads. (Step 1) Reads are discarded if quality <28 at any
position, length <14 or >41, or if the sequence does not occur >100 times in the FASTQ file. (Step 2) Reads are aligned according to a specific
“error type hierarchy.” First reads are aligned, allowing for exact matches only to mature tRNA sequences, then reads that do not map are aligned
allowing for exact matches to pre-tRNA sequences, and then reads that do not map are aligned allowing for one mismatch, then one deletion,
two mismatches, two deletions, and then a three base pair deletion to mature tRNA sequences. (Step 3) tDRs are annotated based on size and
location within either pre-tRNA or mature tRNA. (Step 4) tDRs are quantified based on two features, the fraction of reads aligning to the parent
tRNA and the maximum coverage across all positions of the tRNA. (Step 5) tDRs are visualized as color-coded coverage maps
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our observation that reads with count less than
100 appeared to contribute more noise (small
degraded fragments) than signal (true tDRs).
For datasets with vastly different total number of
reads, it may be advisable to change the threshold
into a percentage of total reads rather than a
number of reads.
Step 2: Filtered reads are aligned to mature and pre-tRNAs
following an “error type” hierarchy
Alignment to tRNA sequences Reads are aligned to
mature and pre-tRNA sequences and not the genome
for four reasons:
(1)The total number of human tRNA genes is not
known and tRNA annotation across the human
genome remains an open area of research.
Therefore, some reads that map to annotated
tRNAs will also map equally well to other
regions of the genome that may also be tRNAs,
but are currently unannotated. Mapping the
small RNA-seq reads to known tRNA sequences
avoids this ambiguity. Of the 615 currently
annotated human tRNA genes in The Genomic
tRNA Database [17] (gtRNAdb), 239 have one or
more annotated identical copies across the
genome. For example, one of the tRNA-Histidine
genes has nine exact copies across the human
genome and one of the tRNA-Aspartate genes
has 11. Mapping reads that are derived from
multi-copy tRNA genes to the whole genome
would complicate tDR quantification. Our
solution is to aggregate the human tRNA genes
that have identical sequences (both pre- and
mature sequences) into “families” and give those
“families” one name (FASTA included with
tDRmapper).
(2)Many tDRs are thought the be derived from
processed, mature tRNAs. As stated previously,
tRNAs undergo specific changes during maturation
and as a result, the sequences of mature tRNAs
do not reflect the genomic template from
which they are produced. These changes during
maturation need to be accounted for when
mapping tRNA-derived RNA reads.
(3)Aligning to annotated tRNA sequences instead of
the genome has the added benefit of a much smaller
search space, which means that mismatches and
deletions can be accounted for in a much more
computationally tractable manner.
tRNA sequences were downloaded from gtRNAdb. To
generate the mature tRNA libraries, we removed the
predicted intronic sequences (if present) and added an
additional 3′ terminal “CCA” to each tRNA. To generate
the pre-tRNA libraries, we included 40 nucleotides of
flanking genomic sequence on either side of the original
tRNA sequence.
Error type Small RNA-seq reads are aligned with an
“error type” hierarchy (Fig. 2) and each “error type” is
annotated and quantified. The reads are first mapped
to mature tRNA sequences allowing for exact matches
only. The reads that do not align are then funneled
to the next step, where the reads are mapped to pre-
tRNA sequences allowing for exact matches only. The
reads that do not align exactly to either the mature
tRNA or the pre-tRNA are then mapped to mature
tRNA sequences, allowing first for one mismatch,
then one deletion, two mismatches, two deletions,
and lastly a three base pair deletion. tDRmapper is
written in a modular fashion, meaning each “error
type” alignment is written in a separate script, enab-
ling the user to easily switch the sequential order in
which the algorithm searches for different “error
types.” This may be useful if, for example, there
emerges a compelling biological reason to prioritize
one deletion over one mismatch or to speed up the
program by not allowing two mismatches.
We allow for and annotate “error types” in reads map-
ping to mature tRNA sequences because mature
eukaryotic tRNAs have on average 17 chemical modifi-
cations [12]. Some of these modifications can lead to
pausing and mis-incorporation of nucleosides, which
manifest as mismatches and deletions in the small RNA-
seq reads [13, 18]. We only allow for mismatches and
deletions when mapping to mature tRNAs, and not pre-
tRNAs, because we assume that only mature tRNAs are
subject to extensive chemical modifications. If future
research overturns this assumption, then the algorithm
can be amended accordingly in a relatively straight-
forward manner. (We note here that some modifica-
tions could also lead to reverse transcriptase aborts,
which would result in an under-representation of
certain types of reads in small RNA-seq data. While
this is an important issue, it is best addressed by ex-
perimental solutions, so we do not discuss this in
tDRmapper).
tRNA modifications have been associated with disease
[19]. We sought to annotate the locations and “error
types” across different tissues and diseases, as these
“error types” may represent sites of chemical modifica-
tion. Figure 3a shows the “error type” proportion across
all tRNAs for all of the datasets analyzed. Overall, most
reads align to tRNAs exactly; however, there are some
tRNAs that have a higher abundance of mismatches and
deletions than others, and also exhibit substantive
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variation in “error types” across tissues (Fig. 3b). For
example, in the liver and seminal fluid samples, ~20 %
of the reads that mapped to tRNA-Glu-CTC-1-7 only
aligned after allowing for a three base pair deletion,
while in colon tissue and H1 cells, this accounted
only for ~4 % and <0.5 %, respectively (Fig. 3b). This
example demonstrates tissue-specific profiles of “error
types” and the importance of allowing for deletions
and mismatches in tDR alignment, since without this
feature, ~50 % of reads aligning to tRNA-Glu-CTC-7-
1 in the liver tissue and seminal fluid samples would
be discarded.
We also found that “error type” profiles can vary by
disease within the same tissue for specific tDRs
(Fig. 3c, d). For example, on average, 8 % of reads
that correspond to tRNA-Pro-CGG-1-3 in the in-
flamed Crohn’s tissue only mapped after allowing for
a three base pair deletion, whereas in 5/6 of the
matched uninflamed tissue, no reads mapped after
allowing for a three base pair deletion (Fig. 3c). Also,
reads that mapped to tRNA-Gly-GCC-1-5 had a sig-
nificantly (P = 0.001) higher incidence of one mis-
match in the non-cancer liver samples compared to
the matched cancer samples (Fig. 3d).
Fig. 3 Proportion of “error types” for specific tRNA-derived RNAs across different tissues and diseases. a-d Relative proportion of “error types” of
reads mapping to a all tRNAs, b tRNA-Glu-CTC-1-7, c tRNA-Pro-CGG-1-3, d tRNA-Gly-GCC-1-5
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Step 3: Aligned reads are named based on read size and
location of derivation from mature or pre-tRNAs
One of the primary challenges in the tDR field is that
there is no standardized naming system. We propose a
nomenclature that is both concise and informative
(Fig. 4). tDRmapper will assign to each tDR a name that
has three components:
1) The first component of the tDR name indicates
the parent tRNA “family” from which the tDR is
derived.
a. For the mature tRNA sequences, the “family”
names consist of four parts, “W-X-Y-Z”, where
W is the tRNA amino acid (sometimes preceded
by “nmt-tRNA,” which means “nuclear encoded
mitochondrial tRNA”), X is the anti-codon, Y is
a unique identifier for each tRNA family, and Z
is the number of mature tRNA genes with the
identical sequence. For example, Asp-GTC-2-11
represents a mature tRNA “family” sequence that
could be derived from 11 different tRNA genes,
has a unique ID, “2”, bears the GTC anti-codon,
and associates with Aspartate. This naming
scheme builds on the nomenclature for tRNAs
used by gtRNAdb.
b. For the pre-tRNA sequences, the “family” names
consist of 6 parts, “pre-W-X-Y-Z.n”. This reflects
the same naming scheme described above in (a),
but with the prefix “pre” and the suffix “.n”.
The “.n” refers to the number of pre-tRNAs from
the W-X-Y mature tRNA family that have the
identical pre-tRNA sequence. From among those
with the identical pre-tRNA sequence, the largest
“Z” is chosen for the “family” name. For
example, the pre-Gly-TCC-2-5.4 sequence
accounts for four pre-tRNAs with identical
sequence. The family members included under
this name are pre-Gly-TCC-2-2, pre-Gly-TCC-
2-3, pre-Gly-TCC-2-4, and pre-Gly-TCC-2-5.
2) The second component of the tDR name indicates
the size of the tDR. tDRmapper determines the
primary tDR associated with a parent tRNA by
counting the number of positions in the tRNA
that have >50 % coverage (where coverage at a
position is defined as the percent of all reads
mapping to the tRNA at that position). If the
primary tDR sequence is <41 nts and = >28 nts,
it is defined as a tRNA-half (tRH), and if it
is >14 nts and <28 nts, it is defined as a tRNA-
fragment (tRF).
Fig. 4 Diagrammatic representation of the naming scheme for tRNA-derived RNAs. a & b Left panel: color-coded structure of tRNAs to illustrate
how tDRs are named. Colors in panel correspond to coverage maps in right panel. Right panel: Example tDRs identified in the datasets analyzed
are shown. Size of dot represents percent of reads mapping at each position within each tRNA shown. a Naming scheme of tDRs derived from
mature tRNAs. Numbers correspond to the “generalized” start and stop positions for each loop. Purple represents the D-loop, “D”; green represents
the anti-codon loop, “A”; dark green represents anti-codon triplet; and yellow represents T-loop, “T”. b Naming scheme of tDRs derived from pre-tRNAs.
Red represents the leader sequence, “0”; orange represents the sequence of the tRNA body,“B”; and yellow represents the trailer sequence, “1”
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3) The last component of the tDR name indicates the
region in the mature or pre-tRNA from which the
read is derived.
a. For the tDRs derived from mature tRNAs
(Fig. 4a), we use a generalized tRNA secondary
structure (Methods). First we determine if a read
is derived from the 5′ or 3′ end of the tRNA.
If not, then we assess whether it overlaps the
D-loop, anti-codon loop, or T-loop by at least one
nucleotide. Details are provided below:
i. “5’” is added as a suffix to the tDR name if the
coverage is >50 % at position +1 of the tRNA
(first nucleotide at the 5′-end).
ii. “3’” is added as a suffix to the tDR name if the
coverage is >50 % at position −7 of the tRNA
(7 nucleotides from the 3′ end). Position −7
was used instead of position −1 due to the
tapering signal (graded reduction in coverage)
observed at the 3′ ends of some tDRs.
iii. “D”, denoting the D-loop, is added as a suffix
to the tDR name if the coverage is >50 %
at any position between 13 and 22, and is
not >50 % at position 1.
iv. “A”, denoting the anti-codon loop, is added
as a suffix to the tDR name if the coverage
is >50 % at any position between 31 and 39,
and not >50 % at position 1 or position −7.
v. “T”, denoting the T-loop, is added as a suffix
to the tDR name if the coverage is >50 %
at any position between −23 and −15, and
not >50 % at position −7. The T-loop is
denoted using positions determined from
the 3′ end (as opposed to the D-loop and
anti-codon loop which are denoted using
positions determined from the 5′-end – see
[iii] and [iv] above) due to variability in the
size of the region between the anti-codon loop
and the T-loop (which contains what is known
as the “variable loop”).
b. For the tDRs derived from pre-tRNAs, we
annotate where in relation to the header,
trailer, and tRNA “body” the tDR is derived
(where “body” is defined as the full-length
tRNA sequence provided by gtRNAdb).
Details are provided below (Fig. 4b):
i. “0” is added as a suffix to the tDR name if the
coverage is >50 % at one or more nucleotides
5′ of the tRNA body, the leader sequence.
ii. “1” is added as a suffix to the tDR name if the
coverage is >50 % at one or more nucleotides
3′ of the tRNA body, the trailer sequence.
This annotation is consistent with the already
described “tRF-1 series” [20], which are tRFs
derived exclusively from trailer sequences.
iii. “B”, denoting tRNA “body”, is added as a suffix
to the tDR name (after either a “0” or a “1”) if
the coverage is >50 % at any position in the
body of the tRNA.
Finally, a primary tDR is only named in the manner
described above if at least one position of the tDR has
coverage >66 % (that is, more than 2/3 of the total reads
mapping to the tRNA). Otherwise the name given is
“undefined” (Fig. 4a). The goal of tDRmapper is to anno-
tate the clearly dominant tDRs. A threshold lower than
66 % would lead to less confidence in the dominance of
a particular tDR. For example, consider a tDR that has a
maximal coverage of 52 % and another that has a max-
imal coverage of 48 %. Technically, the former is the
dominant tDR; however, the two tDRs are close enough
in representation that the differences in coverage could
be due to technical reasons, such as variable read map-
ping efficiencies. Therefore, in such cases, we take a con-
servative approach and deem the dominant tDR to be
ambiguous. The stringent threshold of 66 % is intended
to ensure that a primary tDR is identified only when it
represents the vast majority of the reads mapping to the
parent tRNA.
Step 4: tDRs are quantified based on two features, the
fraction of reads aligning to the parent tRNA and the
maximum coverage across all positions of the tRNA
The tDRs are quantified using the following equation:
Relative abundance ¼
 
of reads mapped to the tRNA
of reads mapped to all tRNA
 
 highest prop: of coverage of tRNA
!
 100
For example, the relative abundance of Val-CAC-1-6 is
4.6 % in the neural progenitor cells (Fig. 5d). In this
sample, there are 45,347 reads mapping to Val-CAC-1-6;
679,288 reads mapping to all the tRNAs; and the highest
proportion of coverage across the tRNA-Val-CAC-1-6 is
0.69, meaning the area with the highest read depth
across tRNA-Val-CAC-1-6 accounts for 69 % of the
reads. By multiplying the total number of reads mapping
to a parent tRNA by the maximum proportion of cover-
age across all base positions in the tRNA, we are com-
puting the fraction of total reads mapping to the parent
tRNA that include the most well represented position in
the tRNA. The primary tDR spans this position; there-
fore, this quantification scheme provides a ceiling on the
fraction of reads that likely correspond to the primary
tDR. In some instances, this approach may overestimate
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the relative abundance of a primary tDR. In the future,
other quantification strategies can also be considered.
Also, every instance a read maps to a tRNA it is
counted once. For example, in the control colon patient
#30, the read “GTTTCCGTAGTGTAGTGGTTATCAC
GTTCGCCT” occurs 1,415,079 times in the FASTQ file,
maps to six different tRNA-Val “families,” and therefore
is quantified as 1,415,079 for each of the families.
There are two reasons for this quantification method:
(1)Small RNA-seq reads will often map with equal
fidelity to several tRNA families. A common
strategy for handling multi-mapping is fractional
assignment of reads. Fractional assignment in its
most simplistic form divides the read count by
the number of locations to which the read aligns.
One goal of fractional mapping is to capture
all locations at which transcription could be
occurring. But, in this scheme, tDRs that derive
from tRNAs with many copies throughout the
genome will be artificially under-quantified. Since
the goal of tDRmapper is to quantify the total
abundance of tDRs, not gain information about
transcriptional regulation of tDRs, we do not use
fractional mapping.
(2)This quantification method has high resolution
since each primary tDR from each parent tRNA
family is quantified separately. However, the
output files do allow for user-driven post-hoc
quantification. For example, the user can decide
to quantify tDRs by aggregating tRNA families
(defined here as those tRNAs with identical
sequence) into even larger super families based
on the isodecoder or the amino acid. This would
not allow for per base resolution, but it would
simplify the signal.
Fig. 5 Examples of mature tRNA coverage maps from each category of human cell types/tissues. a-d Size of dot represents percent of reads mapping
at each position within each tRNA. The color represents each individual nucleotide or the anti-codon positions. The dots overlaid in a variety of shapes
represent each “error type” and the color of these shapes represents the proportion of each “error type” at each position. Coverage map for (a) primary
colon tissue from control subject #31, b the non-sperm fraction of seminal fluid from subjects with prostate cancer, c primary non-cancerous liver
tissue from subject #6 with chronic hepatitis B, and d H1-derived neural progenitor cells
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Step 5: Quantified tDRs are visualized as color-coded
coverage maps
tDRmapper automatically generates a separate visualization
of the pre-tRNA-derived tDR profile and mature tRNA-
derived tDR profile for each sample. Figure 5 shows one
example mature tRNA coverage map from each of the four
categories of cell types/tissues. The y-axis of the tRNA
coverage map shows the top 50 most highly abundant tDRs
in descending order, and also includes the relative abun-
dance (described in Step 4 above). The x-axis shows the
position within the tRNA. Each row displays the percent
read coverage at each position, the nucleotide sequence of
each tRNA, and the positions and proportions of any “error
types” that are present at >5 % of the reads that map to a
given position. This coverage map enables the user to easily
visualize the global tDR profile of a sample.
The coverage maps in Fig. 5 show that tDR profiles
can vary dramatically across tissues. For instance, the
most abundant type of tDRs in the seminal fluid (Fig. 5b)
and liver (Fig. 5c) are of the type tRH-5′, while the colon
(Fig. 5a) and neural progenitors (Fig. 5d) have a greater
abundance of tRF-3’s. It is worth noting that these differ-
ences are not attributable to differences in library prep-
aration or sequencing technology, because the liver and
colon libraries were prepared and sequenced using the
same protocols in the same sequencing facility.
As discussed above, “error types” serve as a proxy
for chemical modifications and therefore can vary
across different tissues and diseases (Fig. 3). Our
coverage maps annotate the specific “error types”
present, enabling comparisons at single nucleotide
resolution. For example, for Glu-CTC-1-1, all of the
examples shown have a one base deletion at positions
7 or 8 accounting for ~20–30 % of the reads that
span that position. However, the liver and seminal
fluid samples also have a three base deletion at any-
where between positions 6 and 10 (though at posi-
tions 7 and 8 only the one base deletion is shown
because it has slightly higher coverage). In humans,
position 10 of the tRNA Glu-CTC has a known N2-
methylguanosine modification, which may cause
reverse transcriptase pausing during the cDNA step,
potentially leading to the observed one base or three
base deletion at exactly this position [21].
Lastly, it is evident from the coverage maps that the
same parental tRNA can produce different primary tDRs
depending on the tissue. For example, Gly-GCC-5-1
produces a tRH-DTA in the colon samples, a tRH-5′ in
the liver and seminal fluid samples, and a tRF-3′ in the
neural progenitor samples (Fig. 5a-d).
Figure 6 shows two pre-tRNA coverage maps. Figure 6a
is from an H1-derived mesendoderm sample, which has
the highest expression of tDRs derived from pre-tRNAs
(pre-tDRs) among all samples analyzed, with 31 % of its
tRNA aligned reads mapping to pre-tRNAs. Figure 6b is
from an inflamed section of colon tissue from a subject
with Crohn’s disease, which has the highest expression
of pre-tDRs among the primary tissue/fluid samples ana-
lyzed, with 1.2 % of its tRNA aligned reads mapping to
pre-tRNAs. These coverage maps are similar to the
coverage maps in Fig. 5, but each dot is colored by loca-
tion in the pre-tRNA instead of each individual base.
We do not show each individual base because we are
not indicating “error type”, since the algorithm searches
only for exact matches to pre-tRNAs. The coverage
maps in Fig. 6 shows that reads can be derived from
both the leader and trailer sequence, as well as from the
region spanning the leader/trailer sequence and the
tRNA body.
Analysis of different categories of cell types/tissues shows
that tDR profiles are specific to tissue, disease and stage
of differentiation
Pearson correlation analysis of all pairs of samples
across the four categories of datasets shows that tDR
profiles correlate strongly between pairs of samples
within the same cell type/tissue (median pair-wise
r2 >0.85, Fig. 7a). This result is indicative of very little
variability across individuals (or biological replicates
in the case of the stem cells) in tDRs within the same
tissue. Generally speaking tDR profiles were far less
correlated between pairs of samples across categories;
however, interestingly, 6/8 liver cancer samples corre-
lated more strongly with the colon tissue samples
(median pair-wise r2 = 0.91) than with the non-cancer
liver samples (median pair-wise r2 = 0.42). The PCA
plot shows several of the liver cancer samples closer
to the colon samples than the non-cancer liver sam-
ples and the hierarchical clustering of the same data
revealed that 6/8 liver cancer samples are in the same
clade as the colon tissue samples (Fig. 7b), supporting
the Pearson correlation analysis (Fig. 7a).
The dominant tDR type produced from the same
tRNA family sometimes varies across different sam-
ples (Figs. 5 and 7c). For example, the dominant tDR
derived from Val-AAC-2-1, which produced a high
abundance tDR in all samples, was a tRH-5′ in most
colon, liver, and seminal fluid samples but a tRF-3′ in
all of the stem and progenitor cells (Fig. 7c and d).
Another example is Glu-CTC-1-7, which produces a
tRH-5′ in most of the primary tissue/fluid samples,
the H1 cells, the trophoblasts, and the neural pro-
genitor samples, but produces a tRH-DA in the
mesendoderm and mesenchymal stem cells.
Reads corresponding to pre-tDRs represent 6–31 % of
all tDR reads in the stem/progenitor cells, >1 % in two
of the colon samples, and <1 % in the rest of the
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samples. In the H1-derived cells, the most highly
expressed pre-tDRs are pre-His-GTG-1-4-tRF-0 and
pre-Arg-CTC-2-1-tRH-1, which are tDRs derived from
the header and leader sequences, respectively. In the
mesendoderm samples, which have the highest pre-tDR
abundance among the samples analyzed, a pre-tDR
(either pre-His-GTG-1-4-tRF-0 or pre-Arg-CTC-2-1-
tRH-1, depending on the sample) is the third-most
abundant tDR after Glu-CTC-1-7-tRH-DA and Glu-
CTC-2-1-tRH-DA.
The primary tissue/fluid samples are characterized by
a few very highly expressed tDRs (Fig. 7d). Specifically,
the colon samples and hepatitis B associated liver cancer
samples are characterized primarily by tDRs derived
from tRNA-Val genes, and the other liver samples by
tDRs derived from tRNA-Gly genes. In contrast, the
Fig. 6 Example of pre-tRNA coverage maps. a & b Size of dot represents percent of reads mapping at each position within each tRNA.
The color represents the location of the pre-tRNA: leader sequence is red, the tRNA body is orange, and the trailer is yellow. Coverage map for (a)
H1-derived mesendoderm cells and b primary tissue from the inflamed section of colon tissue from a subject with Crohn’s disease, #413
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stem and progenitor cells, with the exception of the
neural progenitor cells, are not dominated by a few
highly expressed tDRs, but rather have many tDRs with
moderate expression.
Conclusions
The biomedical significance of tDRs is becoming in-
creasingly apparent and profiling tDRs from small RNA-
seq data sets will define the cell type-specificity of tDRs
and their chemical modifications. In this study we intro-
duced a tool for mapping, naming, and quantifying
tDRs, called tDRmapper, which is designed to handle the
unique and challenging features of small RNAs derived
from tRNAs. We analyzed small RNA-seq data from
four different categories of cell types/tissues using
tDRmapper and found that tDR profiles can differ dra-
matically across different tissues and disease states, that
RNA modifications (as proxied by “error types”) vary by
tissue and disease, and that different tDR species can be
derived from the same parental tRNA depending on the
tissue. tDRmapper not only provides a standardized no-
menclature and quantification scheme for tDRs, but also
includes graphical visualization that facilitates the
discovery of novel tRNA and tDR biology.
Fig. 7 Comparison of tDR profiles across four categories of human cell types/tissues. (A-D) tDR expression profiles for each human cell type/
tissue; every tDR that has >5 % relative abundance in any sample is included in the analysis. a Pearson correlation coefficient heat map. Each cell
in the map represents the correlation coefficient between tDR expression profiles from different two samples. Cells along the diagonal represent
identical samples and are colored in white. Thick white lines divide each category of data sets; thin white lines divide sub-categories of datasets within
each category. Midpoint of color change for bar r2 = 0. b Top panel: plot of principle components. Bottom panel: dendogram from hierarchical clustering
of all tDR profiles. c Primary tDR species heat map. Each cell represents the dominant tDR species in each sample. d tDR expression heat map. Each cell
represents the log10 of the relative tDR abundance of each tDR in each sample
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Methods
tDRmapper package
tDRmapper is available on gitHub (https://github.com/
sararselitsky/tDRmapper). The folder contains all the
scripts needed for tDRmapper to run, the human tRNA
FASTA file, detailed documentation, and the legend for
the coverage maps. tDRmapper was written in Perl
v.5.12.0 and R v3.1.0. The coverage maps were generated
using the ggplot2 R package.
Defining the tRNA generalized secondary structure
Structures of hg19 tRNAs were downloaded from
gtRNAdb. The mode values of the D, anti-codon, and T
loops’ start and stop positions across all tRNAs were used
to determine the “generalized” location of each loop.
Figures and statistical analyses
All statistical analyses were conducted using R. The
hierarchical clustering was performed using the hclust
R package and Ward’s method. The principal compo-
nents analysis was computed using the R package
prcomp. Figures 4, 5, 6, 7 were produced with the R
package gglot2.
Datasets
All the data sets used in this study were publically avail-
able and no ethics approval was required for access.
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